Bioengineering the endocrine pancreas: Intraomental islet transplantation within a biologic resorbable scaffold

Dora Berman-Weinberg, Ruth Molano, Carmen Fotino, Ulisse Ulissi, Jennifer Gimeno, Armando J Mendez, Norman M. Kenyon, Norma S Kenyon, David Andrews, Camillo Ricordi, Antonello Pileggi

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Transplantation of pancreatic islets is a therapeutic option to preserve or restore β-cell function. Our study was aimed at developing a clinically applicable protocol for extrahepatic transplantation of pancreatic islets. The potency of islets implanted onto the omentum, using an in situ-generated adherent, resorbable plasma-thrombin biologic scaffold, was evaluated in diabetic rat and nonhuman primate (NHP) models. Intraomental islet engraftment in the biologic scaffold was confirmed by achievement of improved metabolic function and preservation of islet cytoarchitecture, with reconstitution of rich intrainsular vascular networks in both species. Long-term nonfasting normoglycemia and adequate glucose clearance (tolerance tests) were achieved in both intrahepatic and intraomental sites in rats. Intraomental graft recipients displayed lower levels of serum biomarkers of islet distress (e.g., acute serum insulin) and inflammation (e.g., leptin and a2-macroglobulin). Importantly, low-purity (30:70% endocrine:exocrine) syngeneic rat islet preparations displayed function equivalent to that of pure (>95% endocrine) preparations after intraomental biologic scaffold implantation. Moreover, the biologic scaffold sustained allogeneic islet engraftment in immunosuppressed recipients. Collectively, our feasibility/efficacy data, along with the simplicity of the procedure and the safety of the biologic scaffold components, represented sufficient preclinical testing to proceed to a pilot phase I/II clinical trial.

Original languageEnglish (US)
Pages (from-to)1350-1361
Number of pages12
JournalDiabetes
Volume65
Issue number5
DOIs
StatePublished - May 1 2016

Fingerprint

Bioengineering
Islets of Langerhans Transplantation
Islets of Langerhans
Macroglobulins
Phase II Clinical Trials
Clinical Trials, Phase I
Omentum
Glucose Tolerance Test
Leptin
Serum
Thrombin
Primates
Blood Vessels
Biomarkers
Insulin
Inflammation
Transplants
Safety
Therapeutics

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Bioengineering the endocrine pancreas : Intraomental islet transplantation within a biologic resorbable scaffold. / Berman-Weinberg, Dora; Molano, Ruth; Fotino, Carmen; Ulissi, Ulisse; Gimeno, Jennifer; Mendez, Armando J; Kenyon, Norman M.; Kenyon, Norma S; Andrews, David; Ricordi, Camillo; Pileggi, Antonello.

In: Diabetes, Vol. 65, No. 5, 01.05.2016, p. 1350-1361.

Research output: Contribution to journalArticle

Berman-Weinberg, Dora ; Molano, Ruth ; Fotino, Carmen ; Ulissi, Ulisse ; Gimeno, Jennifer ; Mendez, Armando J ; Kenyon, Norman M. ; Kenyon, Norma S ; Andrews, David ; Ricordi, Camillo ; Pileggi, Antonello. / Bioengineering the endocrine pancreas : Intraomental islet transplantation within a biologic resorbable scaffold. In: Diabetes. 2016 ; Vol. 65, No. 5. pp. 1350-1361.
@article{fa92b4369ae74217a05321cabe562cb4,
title = "Bioengineering the endocrine pancreas: Intraomental islet transplantation within a biologic resorbable scaffold",
abstract = "Transplantation of pancreatic islets is a therapeutic option to preserve or restore β-cell function. Our study was aimed at developing a clinically applicable protocol for extrahepatic transplantation of pancreatic islets. The potency of islets implanted onto the omentum, using an in situ-generated adherent, resorbable plasma-thrombin biologic scaffold, was evaluated in diabetic rat and nonhuman primate (NHP) models. Intraomental islet engraftment in the biologic scaffold was confirmed by achievement of improved metabolic function and preservation of islet cytoarchitecture, with reconstitution of rich intrainsular vascular networks in both species. Long-term nonfasting normoglycemia and adequate glucose clearance (tolerance tests) were achieved in both intrahepatic and intraomental sites in rats. Intraomental graft recipients displayed lower levels of serum biomarkers of islet distress (e.g., acute serum insulin) and inflammation (e.g., leptin and a2-macroglobulin). Importantly, low-purity (30:70{\%} endocrine:exocrine) syngeneic rat islet preparations displayed function equivalent to that of pure (>95{\%} endocrine) preparations after intraomental biologic scaffold implantation. Moreover, the biologic scaffold sustained allogeneic islet engraftment in immunosuppressed recipients. Collectively, our feasibility/efficacy data, along with the simplicity of the procedure and the safety of the biologic scaffold components, represented sufficient preclinical testing to proceed to a pilot phase I/II clinical trial.",
author = "Dora Berman-Weinberg and Ruth Molano and Carmen Fotino and Ulisse Ulissi and Jennifer Gimeno and Mendez, {Armando J} and Kenyon, {Norman M.} and Kenyon, {Norma S} and David Andrews and Camillo Ricordi and Antonello Pileggi",
year = "2016",
month = "5",
day = "1",
doi = "10.2337/db15-1525",
language = "English (US)",
volume = "65",
pages = "1350--1361",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "5",

}

TY - JOUR

T1 - Bioengineering the endocrine pancreas

T2 - Intraomental islet transplantation within a biologic resorbable scaffold

AU - Berman-Weinberg, Dora

AU - Molano, Ruth

AU - Fotino, Carmen

AU - Ulissi, Ulisse

AU - Gimeno, Jennifer

AU - Mendez, Armando J

AU - Kenyon, Norman M.

AU - Kenyon, Norma S

AU - Andrews, David

AU - Ricordi, Camillo

AU - Pileggi, Antonello

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Transplantation of pancreatic islets is a therapeutic option to preserve or restore β-cell function. Our study was aimed at developing a clinically applicable protocol for extrahepatic transplantation of pancreatic islets. The potency of islets implanted onto the omentum, using an in situ-generated adherent, resorbable plasma-thrombin biologic scaffold, was evaluated in diabetic rat and nonhuman primate (NHP) models. Intraomental islet engraftment in the biologic scaffold was confirmed by achievement of improved metabolic function and preservation of islet cytoarchitecture, with reconstitution of rich intrainsular vascular networks in both species. Long-term nonfasting normoglycemia and adequate glucose clearance (tolerance tests) were achieved in both intrahepatic and intraomental sites in rats. Intraomental graft recipients displayed lower levels of serum biomarkers of islet distress (e.g., acute serum insulin) and inflammation (e.g., leptin and a2-macroglobulin). Importantly, low-purity (30:70% endocrine:exocrine) syngeneic rat islet preparations displayed function equivalent to that of pure (>95% endocrine) preparations after intraomental biologic scaffold implantation. Moreover, the biologic scaffold sustained allogeneic islet engraftment in immunosuppressed recipients. Collectively, our feasibility/efficacy data, along with the simplicity of the procedure and the safety of the biologic scaffold components, represented sufficient preclinical testing to proceed to a pilot phase I/II clinical trial.

AB - Transplantation of pancreatic islets is a therapeutic option to preserve or restore β-cell function. Our study was aimed at developing a clinically applicable protocol for extrahepatic transplantation of pancreatic islets. The potency of islets implanted onto the omentum, using an in situ-generated adherent, resorbable plasma-thrombin biologic scaffold, was evaluated in diabetic rat and nonhuman primate (NHP) models. Intraomental islet engraftment in the biologic scaffold was confirmed by achievement of improved metabolic function and preservation of islet cytoarchitecture, with reconstitution of rich intrainsular vascular networks in both species. Long-term nonfasting normoglycemia and adequate glucose clearance (tolerance tests) were achieved in both intrahepatic and intraomental sites in rats. Intraomental graft recipients displayed lower levels of serum biomarkers of islet distress (e.g., acute serum insulin) and inflammation (e.g., leptin and a2-macroglobulin). Importantly, low-purity (30:70% endocrine:exocrine) syngeneic rat islet preparations displayed function equivalent to that of pure (>95% endocrine) preparations after intraomental biologic scaffold implantation. Moreover, the biologic scaffold sustained allogeneic islet engraftment in immunosuppressed recipients. Collectively, our feasibility/efficacy data, along with the simplicity of the procedure and the safety of the biologic scaffold components, represented sufficient preclinical testing to proceed to a pilot phase I/II clinical trial.

UR - http://www.scopus.com/inward/record.url?scp=84964683508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964683508&partnerID=8YFLogxK

U2 - 10.2337/db15-1525

DO - 10.2337/db15-1525

M3 - Article

C2 - 26916086

AN - SCOPUS:84964683508

VL - 65

SP - 1350

EP - 1361

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 5

ER -